Lee's Pharmaceutical Holdings Limited has acquired the Staccato® One Breath Technology® platform and related assets, expanding its product pipeline and strengthening its global partnership with UCB. The proprietary Staccato® platform offers broad therapeutic potential and is described as synergistic and complementary to Lee's Pharm's existing portfolio. Through this transaction, Lee's Pharmaceutical also gains rights as the licensee and manufacturer of Alprazolam Staccato® under the global collaboration with UCB. Company representatives highlighted the deal as a key milestone in Lee's Pharmaceutical's international growth strategy and its commitment to providing innovative therapies for patients with unmet medical needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: GE42284) on December 11, 2025, and is solely responsible for the information contained therein.